A retrospective cross-sectional study on district-based socioeconomic status and prostate cancer diagnosis.
Cancer Screening
Delivery of healthcare
Neighborhood disadvantage
Prostate cancer
Prostate-specific antigen
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
28 Oct 2024
28 Oct 2024
Historique:
received:
25
07
2024
accepted:
04
09
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
aheadofprint
Résumé
Socioeconomic disparities have been linked to delayed prostate cancer diagnosis and poorer outcomes in various countries. This study aims to evaluate the socioeconomic disparities in prostate cancer diagnostics in Vienna, Austria, by examining initial prostate-specific antigen values and age at diagnosis across different districts and nationalities. This retrospective study included 1356 prostate cancer patients treated at the Medical University of Vienna between 2012 and 2022. Influence of residential districts and nationalities of the patients on the initial prostate-specific antigen (iPSA) value and on the age at diagnosis were analyzed. Patient data, including iPSA values, residential districts, and nationalities, were retrieved from the hospital's internal documentation system. The information on average income of residential districts was obtained from the City of Vienna's municipality data. Nationalities were grouped into EU and non-EU categories. Statistical analyses, including linear regression and t‑tests, were performed to examine the relationship between iPSA values, age at diagnosis, and socioeconomic variables. Linear regression was used to analyze the relationship between district income and both iPSA values and age at diagnosis. The study found no significant differences in iPSA values and age at diagnosis between patients from higher income and lower income districts. Additionally, there were no significant differences among individual districts or between EU and non-EU nationals. The findings suggest that the Austrian healthcare system provides equitable access to prostate cancer diagnostics across different socioeconomic groups.
Identifiants
pubmed: 39466416
doi: 10.1007/s00508-024-02449-8
pii: 10.1007/s00508-024-02449-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):7–33.
doi: 10.3322/caac.21763
Bundesanstalt Statistik Österreich. Krebserkrankungen in Österreich: 375.749 Betroffene, 41.775 Neuerkrankungsfälle, 20.337 Sterbefälle. Vienna (AT): Bundesanstalt Statistik Österreich; 2022. p. 4.
Rapiti E, Fioretta G, Schaffar R, Neyroud-Caspar I, Verkooijen HM, Schmidlin F, et al. Impact of socioeconomic status on prostate cancer diagnosis, treatment, and prognosis. Cancer. 2009;115(23):5556–65.
doi: 10.1002/cncr.24607
pubmed: 19787636
Antenor JAV, Han M, Roehl KA, Nadler RB, Catalona WJ. Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. J Urol. 2004;172(1):90–3.
doi: 10.1097/01.ju.0000132133.10470.bb
pubmed: 15201744
Berkowitz SA, Traore CY, Singer DE, Atlas SJ. Evaluating area-based socioeconomic status indicators for monitoring disparities within health care systems: results from a primary care network. Health Serv Res. 2015;50(2):398–417.
doi: 10.1111/1475-6773.12229
pubmed: 25219917
Ito Y, Nakaya T, Nakayama T, Miyashiro I, Ioka A, Tsukuma H, et al. Socioeconomic inequalities in cancer survival: a population-based study of adult patients diagnosed in Osaka, Japan, during the period 1993–2004. Acta Oncol. 2014;53(10):1423–33.
doi: 10.3109/0284186X.2014.912350
pubmed: 24865119
Statistik Austria. Sterbefälle in Wien nach Alter, Geschlecht und Bezirk 2018 bis 2019. Wien: Stadt Wien. 2020. https://www.wien.gv.at/statistik/bevoelkerung/tabellen/sterbefaelle-alter-geschl-bez-zr.html . Accessed 10 July 2024.
Statistik Austria. Wirtschaftsdaten auf Bezirksebene. Wirtschaftskammer Österreich. 2020. https://wko.at/statistik/bezirksdaten/aneinkommen-2019.pdf?_gl=1*1x5qji1*_ga*MTM2NzgxNjcwOS4xNjcyNDk1NTU1*_ga_4YHGVSN5S4*MTY3MjQ5NTU1NC4xLjEuMTY3MjQ5NTU1OS41NS4wLjA.&_ga=2.48212388.280032378.1672495558-1367816709.1672495555 . Accessed 10 July 2024.
Schupp CW, Press DJ, Gomez SL. Immigration factors and prostate cancer survival among Hispanic men in California: does neighborhood matter? Cancer. 2014;120(9):1401–8.
doi: 10.1002/cncr.28587
pubmed: 24477988
Stadt Wien. Einkommen in Wien – Arbeitsmarktstatistik. 2024. https://www.wien.gv.at/statistik/arbeitsmarkt/einkommen/ . Accessed 10 July 2024.
Williams DR, Collins C. US socioeconomic and racial differences in health: patterns and explanations. Annu Rev Sociol. 1995;21(1):349–86.
doi: 10.1146/annurev.so.21.080195.002025
Spitzer S, di Lego V, Kuhn M, Roth C, Berger R. Socioeconomic environment and survival in patients after ST-segment elevation myocardial infarction (STEMI): a longitudinal study for the City of Vienna. BMJ Open. 2022;12(7).
Oberndorfer M, Dorner TE, Brunnmayr M, Berger K, Dugandzic B, Bach M. Health-related and socio-economic burden of the COVID-19 pandemic in Vienna. Health Soc Care Community. 2022;30(4):1550–61.
doi: 10.1111/hsc.13485
pubmed: 34219320
Cosselman KE, Navas-Acien A, Kaufman JD. Environmental factors in cardiovascular disease. Nat Rev Cardiol. 2015;12(11):627–42.
doi: 10.1038/nrcardio.2015.152
pubmed: 26461967
Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 update on prostate cancer epidemiology and risk factors—a systematic review. Eur Urol. 2023;.
Tomic K, Ventimiglia E, Robinson D, Häggström C, Lambe M, Stattin P. Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study. Int J Cancer. 2018;142(12):2478–84.
doi: 10.1002/ijc.31272
pubmed: 29363113
pmcid: 5947133
Freeman VL, Ricardo AC, Campbell RT, Barrett RE, Warnecke RB. Association of census tract-level socioeconomic status with disparities in prostate cancer-specific survival. Cancer Epidemiol Biomarkers Prev. 2011;20(10):2150–9.
doi: 10.1158/1055-9965.EPI-11-0344
pubmed: 21784953
pmcid: 3189295
Coughlin SS. A review of social determinants of prostate cancer risk, stage, and survival. Prostate Int. 2020;8(2):49–54.
doi: 10.1016/j.prnil.2019.08.001
pubmed: 32647640
Dasgupta P, Baade PD, Aitken JF, Ralph N, Chambers SK, Dunn J. Geographical variations in prostate cancer outcomes: a systematic review of international evidence. Front Oncol. 2019;9:238.
doi: 10.3389/fonc.2019.00238
pubmed: 31024842
pmcid: 6463763
Cornford P, van den Bergh RC, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer—2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;.
Sammon JD, Dalela D, Abdollah F, Choueiri TK, Han PK, Hansen M, et al. Determinants of prostate specific antigen screening among black men in the United States in the contemporary era. J Urol. 2016;195(4):913–8.
doi: 10.1016/j.juro.2015.11.023
pubmed: 26598427
McAlister FA, Lin M, Bakal J, Dean S. Frequency of low-value care in Alberta, Canada: a retrospective cohort study. BMJ Qual Saf. 2018;27(5):340–6.
doi: 10.1136/bmjqs-2017-006778
pubmed: 28912198
Gorday W, Sadrzadeh H, de Koning L, Naugler C. Association of sociodemographic factors and prostate-specific antigen (PSA) testing. Clin Biochem. 2014;47(16–17):164–9.
doi: 10.1016/j.clinbiochem.2014.08.006
pubmed: 25130956
Vorsorgeuntersuchung mit PSA-Test: Österreichische Gesundheitskasse. https://www.gesundheitskasse.at/cdscontent/?contentid=10007.896672&portal=oegkportal#:~:text=Im%20Rahmen%20der%20Vorsorgeuntersuchung%20k%C3%B6nnen,einen%20PSA%2DTest%20durchf%C3%BChren%20lassen . Accessed 10 July 2024.
Kappen S, Jürgens V, Freitag MH, Winter A. Attitudes toward and use of prostate-specific antigen testing among urologists and general practitioners in Germany: a survey. Front Oncol. 2021;11:691197. https://doi.org/10.3389/fonc.2021.691197 .
doi: 10.3389/fonc.2021.691197
pubmed: 34150662
pmcid: 8213068
Cussenot O, Taille Y, Portal JJ, Cancel-Tassin G, Roupret M, de la Taille A, et al. A comprehensive national survey of prostate-specific antigen testing and prostate cancer management in France: uncovering regional and temporal disparities. Eur Urol Oncol. 2024; https://doi.org/10.1016/j.euo.2024.02.008 .
doi: 10.1016/j.euo.2024.02.008
pubmed: 38472031